A Heritage of Innovation
We trace our corporate roots to the founding of Behringwerke, a company established in 1904 by
Emil von Behring. CSL Limited was established in 1916 to supply sera, vaccines and other biologicals to the people of Australia.
During the 20th century, leading companies merged, ultimately forming CSL Behring. We are proud of a heritage that has delivered biotherapies for life for more than a century.
Our heritage includes a long legacy of innovation in patient care on which we continue to build to this day. View an
interactive
or
text-only version of our corporate timeline.
1954 |
World’s first pasteurized plasma protein solution |
1979 |
World’s first purified IVIg |
1981 |
World’s first pasteurized factor VIII |
1999 |
Established dedicated prion research laboratory |
2000 |
First company to screen source plasma donations for 5 viruses by NAT |
2000 |
America’s first nanofiltered IVIg |
2004 |
First TSE labeling for IVIg |
Innovation remains an active force at CSL Behring today and is one of our core values. We strive to improve our products, processes and safety and validation systems while seeking to make our products easier and more convenient to use. We also work with regulatory agencies around the world to gain licensure of new therapies and supplemental indications for existing products.
CSL, with whom we share integrated research and development facilities, traces its core plasma therapeutics business to the early 1950s when the company, in collaboration with the Australian Red Cross, started fractionating plasma on behalf of the Australian government. Since listing as a public company in 1994, CSL has become a world leader in plasma therapeutics. CSL integrated R&D facilites are based in Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, United States; Tokyo, Japan; and Broadmeadows and Parkville, Australia.
The only influenza vaccine manufacturer in the Southern Hemisphere, CSL is working closely with public health authorities and the Australian Department of Health to develop and license a safe and effective prototype pandemic influenza vaccine based on the H5N1 avian virus.
In June 2006, GARDASIL® became the first vaccine approved to prevent cervical cancer. GARDASIL is the result of a crucial breakthrough by Professor Ian Frazer and his team at the University of Queensland, collaborative research with CSL scientists and the strong support since 1995 of Merck & Co., Inc., our licensee for this product. GARDASIL has the potential to benefit millions of women and protect them from the second most prevalent cancer in women – a cancer that causes approximately 240,000 deaths annually worldwide. These are just a few of CSL’s many notable achievements in human health over the last century.
* Gardasil is a registered trademark of Merck & Co., Inc.